Literature DB >> 15640377

Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.

Run Tian1, Noriko Koyabu, Satoshi Morimoto, Yukihiro Shoyama, Hisakazu Ohtani, Yasufumi Sawada.   

Abstract

Continuous use of St. John's wort decreases the bioavailabilities of a variety of drugs. This interaction is attributed to the induction of cytochrome P450 3A4 and/or P-glycoprotein. In this study, we aimed to examine the chronic effects of St. John's wort and its constituents, hyperforin and hypericin, on the expression and function of P-glycoprotein in an intestinal cell line, LS 180. We also examined the acute inhibitory effect of St. John's wort on P-glycoprotein by using LLC-GA5-COL150 cells, which overexpress P-glycoprotein. St. John's wort and hyperforin but not hypericin increased the expression of P-glycoprotein in LS 180 cells. Removal of St. John's wort resulted in a restoration of P-glycoprotein level within 48 h. The content of hyperforin in St. John's wort extract was high enough to induce P-glycoprotein, suggesting that the induction of P-glycoprotein by St. John's wort can be almost attributable to hyperforin. The LS 180 cells chronically exposed to St. John's wort or hyperforin exhibited the increase in the function of P-glycoprotein assessed by the efflux of digoxin, and the activities correlated well with P-glycoprotein level. On the other hand, St. John's wort and its two constituents did not show any acute effect on P-glycoprotein-mediated transport of digoxin. St. John's wort induced P-glycoprotein in vitro that functions as a drug efflux pump. Hyperforin is considered to be a primary cause of the inductive effect of St. John's wort. Long-term administration of St. John's wort may cause clinically significant decrease in the plasma concentrations of P-glycoprotein substrates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15640377     DOI: 10.1124/dmd.104.002485

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

2.  Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.

Authors:  Alaa H Abuznait; Shawn G Patrick; Amal Kaddoumi
Journal:  J Pharm Pharm Sci       Date:  2011       Impact factor: 2.327

3.  Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

4.  Successful in vivo tumor visualization using fluorescence laparoscopy in a mouse model of disseminated alveolar rhabdomyosarcoma.

Authors:  Cristian Urla; Sorin Armeanu-Ebinger; Jörg Fuchs; Guido Seitz
Journal:  Surg Endosc       Date:  2014-08-23       Impact factor: 4.584

5.  Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products.

Authors:  Alaa H Abuznait; Hisham Qosa; Nicholas D O'Connell; Jessica Akbarian-Tefaghi; Paul W Sylvester; Khalid A El Sayed; Amal Kaddoumi
Journal:  Food Chem Toxicol       Date:  2011-08-10       Impact factor: 6.023

Review 6.  Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

Authors:  Marie Lund; Tonny Studsgaard Petersen; Kim Peder Dalhoff
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

7.  An assessment of the impact of herb-drug combinations used by cancer patients.

Authors:  Saud M Alsanad; Rachel L Howard; Elizabeth M Williamson
Journal:  BMC Complement Altern Med       Date:  2016-10-18       Impact factor: 3.659

8.  Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells.

Authors:  I S Haslam; K Jones; T Coleman; N L Simmons
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

9.  Does St. John's Wort cause regression in gastrointestinal system adenocarcinomas?

Authors:  Serap Karaarslan; Suna Cokmert; Atilla Cokmez
Journal:  World J Gastrointest Oncol       Date:  2015-11-15

10.  Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial.

Authors:  Michael J Loughren; Evan D Kharasch; Megan C Kelton-Rehkopf; Karen L Syrjala; Danny D Shen
Journal:  Anesthesiology       Date:  2020-03       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.